Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Some people won't mind if you keep your screen visible, but that doesn't mean you should let yourself be distracted. Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results